Melmed S (2006) Acromegaly. New England. J Med 355(24):2558–2573

CAS  Google Scholar 

Frara S, Melin Uygur M, di Filippo L, Doga M, Losa M, Santoro S et al (2022) High Prevalence of Vertebral Fractures Associated With Preoperative GH Levels in Patients With Recent Diagnosis of Acromegaly. J Clin Endocrinol Metab. 107(7):e2843–50. https://academic.oup.com/jcem/article/107/7/e2843/6555665

Giustina A (2023) Acromegaly and bone: an update. Endocrinol Metabolism 38(6):655–666

Article  Google Scholar 

Giustina A (2020) Acromegaly and Vertebral Fractures: Facts and Questions. Trends in Endocrinology and Metabolism. 31(4):274–5. https://doi.org/10.1016/j.tem.2020.01.011

Mazziotti G, Battista C, Maffezzoni F, Chiloiro S, Ferrante E, Prencipe N et al (2020) Treatment of acromegalic osteopathy in real-life clinical practice: the BAAC (bone active drugs in acromegaly) study. J Clin Endocrinol Metab 105(9):E3285–E3292

Article  Google Scholar 

Chiloiro S, Mazziotti G, Giampietro A, Bianchi A, Frara S, Mormando M et al (2018) Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary 21(3):302–308

Article  CAS  PubMed  Google Scholar 

Chiloiro S, Giampietro A, Frara S, Bima C, Donfrancesco F, Fleseriu CM et al (2020) Effects of Pegvisomant and Pasireotide LAR on Vertebral fractures in Acromegaly resistant to first-generation SRLs. J Clin Endocrinol Metab 105(3):4

Article  Google Scholar 

Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP et al (2021) Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol 184(2):217–229

Article  CAS  PubMed  Google Scholar 

Mazziotti G, Canalis E, Giustina A (2010) Drug-induced Osteoporosis: Mechanisms and Clinical Implications. Am J Med. 123(10):877–84. https://linkinghub.elsevier.com/retrieve/pii/S0002934310004675

Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW et al (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 16(3):294–302. http://link.springer.com/https://doi.org/10.1007/s11102-012-0420-x

Mazziotti G, Frara S, Giustina A (2018) Pituitary Diseases and Bone. Endocr Rev. 39(4):440–88. https://academic.oup.com/edrv/article/39/4/440/4975444

Genant HK, Wu CY, van Kuijk C, Nevitt MC (2009) Vertebral fracture assessment using a semiquantitative technique. Journal of Bone and Mineral Research. 8(9):1137–48. https://onlinelibrary.wiley.com/doi/https://doi.org/10.1002/jbmr.5650080915

Chiloiro S, Mormando M, Bianchi A, Giampietro A, Milardi D, Bima C et al (2018) Prevalence of morphometric vertebral fractures in difficult patients with acromegaly with different biochemical outcomes after multimodal treatment. Endocrine 59(2):449–453

Article  CAS  PubMed  Google Scholar 

List EO, Berryman DE, Jensen EA, Kulkarni P, McKenna S, Kopchick JJ (2020) New insights of growth hormone (GH) actions from tissue-specific GH receptor knockouts in mice. Arch Endocrinol Metab 63(6):557–567

Article  Google Scholar 

Park HJ, Ahn SJ, Jang J, Kim S, Park Y, Kim K (2022) Genetic effect of single nucleotide polymorphisms in growth hormone receptor gene on the risk of non-syndromic mandibular prognathism in the Korean population. Orthod Craniofac Res 25(3):437–446

Article  PubMed  Google Scholar 

Marañón-Vásquez GA, Vieira AR, de Carvalho Ramos AG, Dantas B, Romano FL, Palma-Dibb RG et al (2020) GHR and IGF2R genes may contribute to normal variations in craniofacial dimensions: insights from an admixed population. Am J Orthod Dentofac Orthop 158(5):722–730e16

Article  Google Scholar 

Tobón-Arroyave SI, Jiménez-Arbeláez GA, Alvarado-Gómez VA, Isaza-Guzmán DM, Flórez-Moreno GA, Pérez-Cano MI (2018) Association analysis between rs6184 and rs6180 polymorphisms of growth hormone receptor gene regarding skeletal-facial profile in a Colombian population. Eur J Orthod 40(4):378–386

Article  PubMed  Google Scholar 

Lin S, Li C, Li C, Zhang X (2018) Growth hormone receptor mutations related to individual dwarfism. Int J Mol Sci 19(5):1433

Article  PubMed  PubMed Central  Google Scholar 

Mormando M, Nasto LA, Bianchi A, Mazziotti G, Giampietro A, Pola E et al (2014) GH receptor isoforms and skeletal fragility in acromegaly. Eur J Endocrinol 171(2):237–245

Article  CAS  PubMed  Google Scholar 

Pontes J, Madeira M, Lima CHA, Ogino LL, de Paula Paranhos Neto F, de Mendonça LMC et al (2020) Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly. J Endocrinol Invest 43(2):163–171

Article  CAS  PubMed  Google Scholar 

Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B et al (2020) Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 21(4):667–78. https://link.springer.com/https://doi.org/10.1007/s11154-020-09588-z